William B. Fisher

1.7k total citations
39 papers, 1.2k citations indexed

About

William B. Fisher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, William B. Fisher has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in William B. Fisher's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (15 papers) and Cancer therapeutics and mechanisms (9 papers). William B. Fisher is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (15 papers) and Cancer therapeutics and mechanisms (9 papers). William B. Fisher collaborates with scholars based in United States, India and Belgium. William B. Fisher's co-authors include Rafat Ansari, Nasser H. Hanna, Patrick J. Loehrer, Daniel Bruetman, Ramaswamy Govindan, R Gonin, L H Einhorn, Cynthia S. Johnson, Constantin T. Yiannoutsos and Sreenivasa Nattam and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

William B. Fisher

38 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William B. Fisher United States	17	846	760	212	160	86	39	1.2k
P.A. Burt United Kingdom	17	1.0k 1.2×	810 1.1×	140 0.7×	145 0.9×	117 1.4×	48	1.4k
Josiane Otto France	20	906 1.1×	1.1k 1.4×	228 1.1×	98 0.6×	204 2.4×	59	1.6k
N.H. Gower United Kingdom	13	930 1.1×	871 1.1×	216 1.0×	217 1.4×	60 0.7×	17	1.3k
Colin Trask United Kingdom	11	488 0.6×	543 0.7×	159 0.8×	228 1.4×	40 0.5×	12	837
C. Cripps Canada	18	401 0.5×	712 0.9×	203 1.0×	149 0.9×	50 0.6×	54	1.2k
Salitha Reddy United States	18	552 0.7×	571 0.8×	77 0.4×	120 0.8×	69 0.8×	29	1.3k
Hiroshi Semba Japan	15	962 1.1×	629 0.8×	110 0.5×	50 0.3×	53 0.6×	46	1.1k
L. Falchero France	18	1.0k 1.2×	673 0.9×	172 0.8×	44 0.3×	333 3.9×	71	1.4k
Indrajit Fernando United Kingdom	15	264 0.3×	702 0.9×	109 0.5×	198 1.2×	131 1.5×	48	1.3k
A. Brewster United Kingdom	16	499 0.6×	587 0.8×	76 0.4×	92 0.6×	91 1.1×	33	1.2k

Countries citing papers authored by William B. Fisher

Since Specialization

Citations

This map shows the geographic impact of William B. Fisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William B. Fisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William B. Fisher more than expected).

Fields of papers citing papers by William B. Fisher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William B. Fisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William B. Fisher. The network helps show where William B. Fisher may publish in the future.

Co-authorship network of co-authors of William B. Fisher

This figure shows the co-authorship network connecting the top 25 collaborators of William B. Fisher. A scholar is included among the top collaborators of William B. Fisher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William B. Fisher. William B. Fisher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Durm, Greg Andrew, Sandra K. Althouse, Alia Sadiq, et al.. (2018). OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 13(10). S321–S321. 6 indexed citations

Durm, Greg Andrew, Sandra K. Althouse, Ahad A. Sadiq, et al.. (2018). Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.. Journal of Clinical Oncology. 36(15_suppl). 8500–8500. 43 indexed citations

Sierawski, Brian D., Robert A. Reed, Kevin M. Warren, et al.. (2017). CubeSat: Real-time soft error measurements at low earth orbits. 54. 3D–1.1. 4 indexed citations

Sierawski, Brian D., Kevin M. Warren, Andrew L. Sternberg, et al.. (2016). CubeSats and Crowd-Sourced Monitoring for Single Event Effects Hardness Assurance. IEEE Transactions on Nuclear Science. 64(1). 293–300. 6 indexed citations

Fisher, William B., Rafat Ansari, Erwin Robin, et al.. (2012). Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe. Journal of Thoracic Oncology. 7(4). 760–763. 22 indexed citations

Jalal, Shadia I., A. Melnyk, Donald Richards, et al.. (2011). Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Annals of Oncology. 23(7). 1730–1738. 58 indexed citations

Harb, Wael A., Daniel S. Bradford, José A. Bufill, et al.. (2010). Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116. Journal of Thoracic Oncology. 5(11). 1815–1820. 23 indexed citations

Chang, King‐Jen, William B. Fisher, Daniel E. Kenady, et al.. (2009). Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS). Journal of Clinical Oncology. 27(15_suppl). 4605–4605. 5 indexed citations

Jalal, Shadia I., Rafat Ansari, Ramaswamy Govindan, et al.. (2009). Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study. Journal of Thoracic Oncology. 4(1). 93–96. 25 indexed citations

10.

Fisher, William B., Daniel Bruetman, J. McClean, et al.. (2008). Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology. 3(4). 374–379. 19 indexed citations

11.

Hanna, Nasser H., M. Neubauer, Rafat Ansari, et al.. (2007). Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023. Journal of Clinical Oncology. 25(18_suppl). 7512–7512. 41 indexed citations

12.

Suvannasankha, Attaya, Christopher A. Fausel, Beth E. Juliar, et al.. (2007). Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21. The Oncologist. 12(1). 99–106. 36 indexed citations

13.

Ganjoo, Kristen N., Michael J. Robertson, William B. Fisher, et al.. (2005). A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin Lymphomas. American Journal of Clinical Oncology. 28(2). 169–172. 6 indexed citations

14.

Loehrer, Patrick J., Rafat Ansari, R Gonin, et al.. (1995). Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.. Journal of Clinical Oncology. 13(10). 2594–2599. 121 indexed citations

15.

Blanke, Charles D., Rafat Ansari, R. Mantravadi, et al.. (1995). Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol.. Journal of Clinical Oncology. 13(6). 1425–1429. 111 indexed citations

16.

Fisher, William B., et al.. (1991). Clinical trials in cancer therapy: Efforts to improve patient enrollment by community oncologists. Medical and Pediatric Oncology. 19(3). 165–168. 30 indexed citations

17.

Roth, Bruce J., et al.. (1991). Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group. Cancer. 68(2). 248–252. 16 indexed citations

18.

Lauer, Richard C., William B. Fisher, Kenneth Pennington, et al.. (1988). Etoposide and Split-Dose Cisplatin in Bronchogenic Carcinoma. American Journal of Clinical Oncology. 11(6). 634–635. 3 indexed citations

19.

Einhorn, L H, Patrick J. Loehrer, Stephen D. Williams, et al.. (1986). Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 4(7). 1037–1043. 106 indexed citations

20.

Fisher, William B.. (1977). Exchange Transfusion in Acute Thrombotic Thrombocytopenic Purpura: Case Report. Military Medicine. 142(10). 789–790. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact